Monopar Therapeutics's 15min chart shows KDJ Golden Cross and Bullish Marubozu signals.

Based on the 15-minute chart of Monopar Therapeutics, a technical indicator known as the KDJ Golden Cross has been triggered, accompanied by a Bullish Marubozu at 09/12/2025 12:45. This suggests a shift in the momentum of the stock price towards the upside, with potential for further growth. The buyers are currently in control of the market, and it is likely that bullish momentum will continue.

On September 12, 2025, at 12:45, Monopar Therapeutics' 15-minute chart triggered a Golden Cross in the KDJ indicator, accompanied by a bullish Marubozu candlestick pattern. This technical signal suggests a significant shift in the stock's momentum towards the upside, indicating potential for further growth. The buyers are currently in control of the market, and it is likely that the bullish momentum will continue.

The Golden Cross in the KDJ indicator signifies a crossover of the K and D lines, typically indicating a change in the trend from bearish to bullish. This is a strong technical signal that Monopar Therapeutics is poised for upward movement Employers Holdings' 15-min chart shows KDJ Golden ...^[1]. The bullish Marubozu candlestick pattern, characterized by a long body with no shadows above or below, indicates strong buying pressure. This pattern is often associated with a continuation of the current trend, suggesting that the price is likely to move higher.

These signals follow a broader trend of Golden Crosses and bullish Marubozu formations observed in several other stocks, including ASGN and Cushing NextGen. Technical analysis provides valuable insights into potential stock price movements, but it is crucial for investors to consider these signals in conjunction with fundamental analysis and broader market conditions.

As of July 7, 2025, several notable companies have seen updates to their analyst ratings and price targets, reflecting the evolving opinions of financial experts. Positive Outlook: Alnylam Pharma (ALNY) received a "Buy" rating from Jefferies with a price target of $384.00. Chime Financial (CHYM) was initiated with an "Overweight" rating by multiple firms, including Morgan Stanley and Barclays, with targets ranging from $39.00 to $40.00. CryoPort (CYRX) was rated "Buy" by BTIG Research with a price target of $10.00. Datadog (DDOG) had its price target raised from $150.00 to $175.00 by Bank of America, reiterating a "Buy" rating. Energy Transfer (ET) was initiated with a "Buy" rating by TD Cowen with a price target of $22.00. Grab (GRAB) was rated "Buy" by Jefferies with a price target of $5.70, indicating a 20.94% upside. Home Depot (HD) was rated "Buy" by TD Cowen with a price target of $470.00. Intuit (INTU) was rated "Buy" by Morgan Stanley with a price target of $900.00. JPMorgan Chase & Co. (JPM) had a $298.00 target set by Evercore ISI with an "Outperform" rating. Kinder Morgan (KMI) was initiated with a "Buy" rating by TD Cowen. Lam Research (LRCX) had its "Buy" rating reiterated by Citigroup. MACOM Technology Solutions (MTSI) had its target raised from $136.00 to $154.00 by Truist Financial, maintaining a "Buy" rating. Monopar Therapeutics (MNPR) was initiated with an "Overweight" rating by Cantor Fitzgerald and a target of $74.00. Norwegian Cruise Line (NCLH) received a "Buy" rating from Jefferies with a price target of $29.00. Oracle (ORCL) received a "Buy" rating from UBS with a $250.00 target. Oportun Financial (OPRT) was rated "Buy" at B. Riley Financial with an $11.00 price target. Ovintiv (OVV) was rated "Buy" at Barclays Capital with a price target of $55.00. Phibro Animal Health (PAHC) was upgraded at JPMorgan Chase from Neutral to Overweight, with the price target raised from $25.00 to $35.00. Progressive (PGR) was downgraded by Morgan Stanley from Overweight to Equal Weight, with a price target of $290.00. Pulse Biosciences (PLSE) was initiated by Oppenheimer with an "Outperform" rating and a $22.00 price target. PTC (PTC) had its Overweight rating reiterated by KeyCorp Bank. Rockwell Automation (ROK) was initiated by CICC Research with a "Buy" rating and a price target of $320.00 Employers Holdings' 15-min chart shows KDJ Golden ...^[1].